Publications by authors named "Rony Pain"
Article Synopsis
- Acute myeloid leukemia (AML) is a serious blood cancer with few treatment options and a high chance of coming back after chemotherapy.
- Researchers studied N-myristoylation, a protein modification linked to cancer cell survival, and found that the level of N-myristoyltransferase 2 (NMT2) can indicate patient outcomes.
- They tested a drug called zelenirstat, which inhibits myristoylation, and found it caused cancer cell death and reduced leukemia in models, suggesting it could be an effective new treatment for AML patients with poor prognoses.
Background: In humans, two ubiquitously expressed N-myristoyltransferases, NMT1 and NMT2, catalyze myristate transfer to proteins to facilitate membrane targeting and signaling. We investigated the expression of NMTs in numerous cancers and found that NMT2 levels are dysregulated by epigenetic suppression, particularly so in hematologic malignancies. This suggests that pharmacological inhibition of the remaining NMT1 could allow for the selective killing of these cells, sparing normal cells with both NMTs.
View Article and Find Full Text PDF